TNF and cancer: Even if they did not demonstrate a significant difference in recurrent cancer rate in patients exposed or not exposed to any immunosuppressants, they noticed that only patients on AZA developed a recurrent cancer, while none on MTX, anti-TNFα, or other immunosuppressants developed a new or recurrent cancer.